{"id":877829,"date":"2025-08-21T07:42:15","date_gmt":"2025-08-21T11:42:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/"},"modified":"2025-08-21T07:42:15","modified_gmt":"2025-08-21T11:42:15","slug":"pyxis-oncology-to-participate-in-september-investor-and-industry-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/","title":{"rendered":"Pyxis Oncology to Participate in September Investor and Industry Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Aug.  21, 2025  (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.<\/p>\n<p align=\"left\">Investor Conferences<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>2025 Cantor Global Healthcare Conference<\/strong>, New York, NY, Wednesday, September 3, 2:45 p.m. ET \u2013 Fireside chat and investor one-on-one meetings.<\/p>\n<\/li>\n<li>\n          <strong>H.C. Wainwright 27<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Investment Conference<\/strong>, New York, NY, Monday, September 8, 10:30 a.m. ET \u2013 Fireside chat and investor one-on-one meetings.<\/li>\n<\/ul>\n<p align=\"left\">Industry Conference<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>2<\/strong><br \/>\n          <sup><br \/>\n            <strong>nd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual ADC and Novel Conjugates Partnering and Investment Summit<\/strong>, Boston, MA, Tuesday, September 9, 3:20 p.m. ET \u2013 Company presentation (not webcast).<\/li>\n<\/ul>\n<p align=\"left\">Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1QN5ZAcl42c6T1g1LB_ogJpPB2oh2CHXOZBTCYc5e1JWUb0VPypzu9ryBvbw02NSLDPPqlvgq8NENOlwfpbTlYkX-EGSXiSXVDeawL929A8=\" rel=\"nofollow\" target=\"_blank\">ir.pyxisoncology.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About Pyxis Oncology, Inc.<\/strong><br \/>\n        <br \/>Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R\/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1\/2 combination study of MICVO and Merck\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab), in patients with R\/M HNSCC and other advanced solid tumors.<\/p>\n<p align=\"left\">To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jpvUBNZosiNaKGNbsNX7rKT0rb-cyuxZ-PzFXcg11SRCDwP3vDIGItCVCRp5TlEzfGzoNWVmE-A-9W9-3nXbzSogOVdPBezbz24yEnO9mqc=\" rel=\"nofollow\" target=\"_blank\">www.pyxisoncology.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZtdEEdCOYseZDGwELVPBwfb8tTq49gWx3qTjcUATzNTp-clP-8PxljULfMuGHpvdVNa3ibhCFLsPCTBZV9rGyQ==\" rel=\"nofollow\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M3PVh67aPj_q70shC2akep-J1FP8cIam3lqBwAc6F9pImYsG7jIjBN8QZLAJ9L7ytFYVfw_a8WjhU_y31TBtQd7ujzaFIWCgo2TXcnSAhAO5hiwIOVq8Hcb1wWieYSYz\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Pyxis Oncology Contact<\/strong><br \/>\n        <br \/>Jitu Wadhane<br \/>Principal Financial and Accounting Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B8DGJ1Qc9upw9hQtcx58xXG3O3Fd0E_kVNNKbNoWx-LRUq5Y-R16uP89LvTocMc8CLRbbpf_c44_w43pDVttvWqky4ANE0JzSv_FGjUtd_Y=\" rel=\"nofollow\" target=\"_blank\">IR@pyxisoncology.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media<\/strong><br \/>\n        <br \/>Molly Devlin<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tJ30rVQgcJSLyWAZ4l7YtBVisOmIQ7OBr629dS4ciUJxC1AQR0ocas9ctpisUZ_VUqkme3Zt3pCcRUU442IbCeYNHZxRQ8z26S8qqIFfzfaKg0dmAbM9yAGs93-7l-14\" rel=\"nofollow\" target=\"_blank\">mdevlin@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjZkY2U4MDktNTI1OS00MTE5LTgzYTItYTZlNGVkMzE0YzFlLTEyMjA3ODItMjAyNS0wOC0yMS1lbg==\/tiny\/Pyxis-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET \u2013 Fireside chat and investor one-on-one meetings. H.C. Wainwright 27 th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET \u2013 Fireside chat and investor one-on-one meetings. Industry Conference 2 nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET \u2013 Company presentation (not webcast). Live webcasts &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pyxis Oncology to Participate in September Investor and Industry Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-877829","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET \u2013 Fireside chat and investor one-on-one meetings. H.C. Wainwright 27 th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET \u2013 Fireside chat and investor one-on-one meetings. Industry Conference 2 nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET \u2013 Company presentation (not webcast). Live webcasts &hellip; Continue reading &quot;Pyxis Oncology to Participate in September Investor and Industry Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T11:42:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pyxis Oncology to Participate in September Investor and Industry Conferences\",\"datePublished\":\"2025-08-21T11:42:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/\"},\"wordCount\":300,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/\",\"name\":\"Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\",\"datePublished\":\"2025-08-21T11:42:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyxis Oncology to Participate in September Investor and Industry Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk","og_description":"BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET \u2013 Fireside chat and investor one-on-one meetings. H.C. Wainwright 27 th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET \u2013 Fireside chat and investor one-on-one meetings. Industry Conference 2 nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET \u2013 Company presentation (not webcast). Live webcasts &hellip; Continue reading \"Pyxis Oncology to Participate in September Investor and Industry Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T11:42:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pyxis Oncology to Participate in September Investor and Industry Conferences","datePublished":"2025-08-21T11:42:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/"},"wordCount":300,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/","name":"Pyxis Oncology to Participate in September Investor and Industry Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=","datePublished":"2025-08-21T11:42:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTc4MSM3MTA4OTY5IzIyMDkyMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pyxis Oncology to Participate in September Investor and Industry Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=877829"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=877829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=877829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=877829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}